Skip to content
The Policy VaultThe Policy Vault

Invanz (ertapenem) — CareFirst (Caremark)

Community acquired pneumonia in adult patients and pediatric patients (age ≥ 3 months)

Initial criteria

  • Must be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria
  • When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy
  • In the absence of culture and susceptibility data, local epidemiology and susceptibility patterns should guide empiric selection of therapy